# US Virology Specimen Collection Market

> US Virology Specimen Collection Market Research Report: Size, Share, Trend Analysis By Product Type (Swabs, Viral Transport Media, Blood Collection Kits, Others), By Applications (Diagnostics, Research) and By End Users (Hospitals & Clinics, Diagnostic Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.3%
- **2024:** $ 1,798.55 Million
- **2025:** $ 1,893.88 Million
- **2035:** $ 3,174.92 Million
- **Key Players:** Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), BD (US), Qiagen (DE), PerkinElmer (US), Hologic (US), Bio-Rad Laboratories (US), Merck KGaA (DE)

**Report ID:** MRFR/HC/14862-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-virology-specimen-collection-market-16390

---

## Market Summary

## **US Virology Specimen Collection Market Overview**

As per MRFR analysis, the US Virology Specimen Collection Market Size was estimated at 1.46 (USD Billion) in 2023. The US Virology Specimen Collection Market Industry is expected to grow from 1.65(USD Billion) in 2024 to 2.95 (USD Billion) by 2035. The US Virology Specimen Collection Market CAGR (growth rate) is expected to be around 5.424% during the forecast period (2025 - 2035)****

### **Key US Virology Specimen Collection Market Trends Highlighted**

The US Virology Specimen Collection Market is influenced by several key market drivers. An increasing prevalence of viral infections, such as influenza, COVID-19, and hepatitis, has accelerated the demand for efficient specimen collection methods.
The rise in awareness regarding the importance of timely diagnosis and surveillance of viral diseases also contributes to market growth. Additionally, advancements in technology, including automation and the integration of digital health solutions, are transforming specimen collection processes, making them more efficient and reliable.

There are several opportunities to be explored in this market. The rising population and the increased demand for preventive healthcare services open avenues for innovation in specimen collection products and services. Moreover, partnerships between healthcare providers, laboratories, and technology companies can lead to improved specimen collection kits that facilitate more accurate and faster results. 
Enhanced regulatory support for public health initiatives presents further opportunities for market development, particularly in expanding access to efficient testing methods across underserved populations.

In recent times, there has been a notable trend towards more user-friendly and home-based specimen collection. The shift towards at-home collection kits, driven in part by the COVID-19 pandemic, has made testing more accessible and convenient for patients, particularly in remote areas. This trend is further supported by increasing telehealth adoption, which encourages more individuals to seek testing. Additionally, a greater focus on improving the quality and safety of specimen collection is evident, as healthcare institutions strive to minimize contamination and ensure more accurate results.

Overall, these trends shape the landscape of the US Virology Specimen Collection Market, promoting a proactive approach to viral disease management and detection. As per MRFR analysis, the US Virology Specimen Collection Market Size was estimated at 1.46 (USD Billion) in 2023. The US Virology Specimen Collection Market Industry is expected to grow from 1.65(USD Billion) in 2024 to 2.95 (USD Billion) by 2035. The US Virology Specimen Collection Market CAGR (growth rate) is expected to be around 5.424% during the forecast period (2025 - 2035).

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Virology Specimen Collection Market Drivers**

### **Rising Incidence of Viral Infections**

The increase in viral infections, notably influenza, COVID-19, and Hepatitis viral cases, significantly drives the US [Virology Specimen Collection Market Industry](../../../reports/virology-specimen-collection-market-10798). The Centers for Disease Control and Prevention (CDC) has reported that, for instance, the number of detected influenza cases has escalated, with a 30% rise in hospitalizations over the past two flu seasons. Furthermore, the continued prevalence of COVID-19 reinforces the need for efficient specimen collection methods to support diagnostic testing.

With companies like Abbott Laboratories and Thermo Fisher Scientific innovating in specimen collection technologies and enhancing efficiency, the demand for competent specimen collection continues to grow. This trend is bolstered by the enduring public health priorities aimed at controlling viral outbreaks and promoting early detection, thereby positively influencing the US Virology Specimen Collection Market.

### **Advancements in Diagnostic Technologies**

Rapid advancements in diagnostic technologies play a crucial role in boosting the US Virology Specimen Collection Market Industry. The shift towards molecular diagnostics and point-of-care testing, enabled by significant contributions from organizations such as Cepheid and QIAGEN, has improved the accuracy of virology testing. According to the National Health Statistics Reports, as of 2022, nearly 60% of US laboratories reported adopting molecular diagnostics, reflecting a 25% increase over the past five years.

As these advanced technologies necessitate efficient specimen collection processes to ensure reliable results, the sustained investment in this arena indicates strong growth prospects for the market.

### **Increased Government Funding for Health Initiatives**

Government funding aimed at bolstering public health initiatives significantly impacts the US Virology Specimen Collection Market Industry. The Health Resources and Services Administration (HRSA) announced increased funding for vaccine distribution and specimen collection initiatives, allocating nearly $800 million in the last fiscal year. This funding surge is driven by the urgent need for improved testing capacities stemming from the COVID-19 pandemic.

As state governments also respond with their grants and improvement programs to enhance local health department capabilities, companies involved in virology specimen collection are poised to benefit immensely, resulting in robust growth within the market.

## **US Virology Specimen Collection Market Segment Insights**

### **Virology Specimen Collection Market Product Type Insights**

The US Virology Specimen Collection Market is characterized by diverse product types, each playing a vital role in the efficient collection of virology specimens, which are crucial for diagnostics and research. Among these, Swabs are a predominant choice due to their ease of use and effectiveness in sample collection, particularly in diagnosing viral infections such as influenza and COVID-19. 
Viral Transport Media (VTM) also holds significant importance as it ensures the stability and viability of viral specimens during transportation to diagnostic labs, thereby facilitating accurate viral testing.

Blood Collection Kits are essential for serological testing, allowing for the identification of viral diseases through blood-based assays, which has become increasingly important in managing pandemics and outbreaks. 
Additionally, the category labeled as "Others" encapsulates a variety of additional collection devices and kits that address specific needs, such as specialty testing or emerging viruses. Each product type addresses unique technical specifications and regulatory guidelines, contributing to the growing US Virology Specimen Collection Market revenue.

This diverse segmentation reflects a broader trend in public health that emphasizes the significance of reliable specimen collection in supporting effective diagnostic capabilities. The growth of the US Virology Specimen Collection Market statistics reveals a landscape where innovation and compliance with health regulations drive advancements across all product types while ensuring better healthcare outcomes. As the demand for efficient, reliable specimen collection increases due to ongoing public health challenges, these product types will continue to gain traction, shaping the future of the virology specimens landscape in the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Virology Specimen Collection Market Application Insights**

The Application segment of the US Virology Specimen Collection Market plays a crucial role in addressing public health needs through efficient testing and analysis. This segment is primarily divided into Diagnostics and Research, both of which are vital for understanding and combating viral infections.
 Diagnostics focuses on the rapid identification of pathogens, enabling timely treatment interventions and containment of outbreaks, while Research fosters the development of innovative diagnostic tools and therapeutic interventions, enhancing the scientific community's understanding of virology.

The Diagnostics aspect is essential as it aids in early detection of infections, thus improving patient outcomes and minimizing the spread of diseases. Meanwhile, the Research component drives advancements in technology and methodology, aligning with government initiatives to bolster public health infrastructure in the US.
 With increasing government investments and heightened awareness of infectious diseases, this segment is expected to benefit significantly, showcasing substantial growth opportunities in the coming years. As rising viral infections necessitate a robust specimen collection framework, the US Virology Specimen Collection Market remains a critical focal point for healthcare professionals and researchers alike.

### **Virology Specimen Collection Market End User Insights**

The US Virology Specimen Collection Market is significantly shaped by its End User segment, which includes Hospitals and Clinics, Diagnostic Centers, and other healthcare settings. 
Hospitals and Clinics play a crucial role in the specimen collection process due to their capacity to provide immediate care and perform tests for various viral infections. This segment often holds a major share of the market, driven by the increasing number of patients seeking diagnosis and treatment for viral diseases.

Diagnostic Centers, specializing in laboratory testing, are also vital as they focus on accurate and timely diagnoses, contributing to improved patient outcomes. This segment is witnessing growth owing to the rising demand for specialized testing methods and procedures, including those related to emerging viruses. Additionally, other healthcare facilities, which may include home care and research-based settings, are increasingly participating in virology specimen collection, providing diverse opportunities for growth and innovation in response to the evolving healthcare landscape.

Overall, the diverse needs of these End Users create a dynamic environment conducive to advancements and increased efficiency in the US Virology Specimen Collection Market.

## **US Virology Specimen Collection Market Key Players and Competitive Insights**

The US Virology Specimen Collection Market has become increasingly dynamic due to several factors such as the rise in infectious diseases, advancements in diagnostic technologies, and a growing emphasis on early detection and prevention strategies. As healthcare providers and laboratories strive to improve patient outcomes, the demand for effective specimen collection solutions remains high. Competitive insights reveal a landscape marked by innovation and strategic partnerships, as companies aim to introduce enhanced products tailored to the specific needs of virology diagnostics.

The market is characterized by the presence of established players who invest heavily in research and development to maintain their competitive edge, alongside emerging companies that are introducing novel solutions.

Hologic has established a strong presence in the US Virology Specimen Collection Market, leveraging its expertise in molecular diagnostics to provide high-quality products designed for efficient specimen collection. The company is known for its commitment to innovation, resulting in a range of user-friendly specimen collection kits that facilitate the testing process while ensuring the integrity of samples. Hologic’s strengths lie in its robust reputation for reliability and accuracy, which are critical in virology diagnostics.

Furthermore, the company has strategically invested in partnerships and collaborations that enhance its reach within the healthcare sector, allowing it to remain a significant player in the competitive landscape.

BioRad Laboratories plays a pivotal role in the US Virology Specimen Collection Market by offering a diverse portfolio of specialized products and services aimed at enhancing laboratory efficiency and accuracy in virology testing. The company’s strengths stem from its long-standing expertise in life sciences and clinical diagnostics, bolstered by its investment in innovative technologies that streamline specimen collection and processing. BioRad’s key offerings include specialized reagents, kits, and equipment that cater to the varied needs of laboratories conducting virology testing.

Additionally, the company has been active in strengthening its market presence through strategic mergers and acquisitions, which have expanded its product range and customer base in the US. This proactive approach has enabled BioRad to fortify its position in the market while continually adapting to the evolving demands of virology diagnostics.

### **Key Companies in the US Virology Specimen Collection Market Include**

## **US Virology Specimen Collection Market Industry Developments**

In recent months, the US Virology Specimen Collection Market has seen significant developments, particularly spurred by advancements in diagnostic capabilities due to increased demand for testing amid ongoing health concerns. Companies such as Hologic and Abbott Laboratories have reported growth in their product offerings, expanding their virology-related diagnostic tools. 
Additionally, in March 2023, Roche and Cepheid collaborated to enhance their collection methods for better efficiency and accuracy. The year 2022 marked a pivotal moment when Medline Industries introduced new logistics services to streamline specimen transportation, positively impacting market dynamics.

Furthermore, in July 2023, PerkinElmer announced an acquisition of SeraCare Life Sciences, aiming to strengthen its portfolio in molecular diagnostics. As the market continues to evolve, the focus on Research and Development activities remains crucial, with significant investments from Thermo Fisher Scientific and BioRad Laboratories being reported to improve specimen handling technologies.
 With the rise of personalized medicine and rapid testing scenarios, there is a robust upward trajectory in market growth, driven by innovation and strategic partnerships among key players in the industry.

## **US Virology Specimen Collection Market Segmentation Insights**

### **Virology Specimen Collection Market Product Type Outlook**

### **Virology Specimen Collection Market Application Outlook**

### **Virology Specimen Collection Market End User Outlook**

## Market Drivers

### Emergence of Point-of-Care Testing

The emergence of point-of-care (POC) testing is reshaping the landscape of the virology specimen-collection market. POC testing allows for rapid diagnosis and immediate treatment decisions, which is particularly crucial in managing viral infections. The convenience and speed of POC testing are driving its adoption across various healthcare settings, including clinics and emergency departments. Market analysis indicates that the POC testing segment is expected to grow at a CAGR of around 8% over the next few years. This growth is likely to stimulate demand for innovative specimen-collection devices that are compatible with POC testing methodologies, thereby enhancing the overall efficiency of the virology specimen-collection market.

### Rising Demand for Diagnostic Testing

The increasing prevalence of viral infections in the US has led to a heightened demand for diagnostic testing, which directly influences the virology specimen-collection market. As healthcare providers strive to enhance patient outcomes, the need for accurate and timely testing has become paramount. According to recent data, the diagnostic testing market is projected to grow at a CAGR of approximately 7% over the next few years. This growth is likely to drive investments in specimen-collection technologies, thereby expanding the virology specimen-collection market. Furthermore, the emphasis on early detection and preventive healthcare measures is expected to further bolster the demand for efficient specimen-collection methods, ensuring that healthcare facilities are equipped to handle the increasing volume of tests.

### Integration of Automation in Laboratories

The integration of automation technologies in laboratories transforms the virology specimen-collection market. Automated systems enhance the efficiency and accuracy of specimen handling, reducing the risk of contamination and human error. As laboratories seek to optimize workflows, the adoption of automated specimen-collection devices is on the rise. Reports indicate that the automation market in laboratories is expected to grow significantly, with a projected increase of around 10% annually. This trend suggests that laboratories are increasingly investing in advanced technologies to streamline operations, which in turn is likely to create a favorable environment for the virology specimen-collection market. The shift towards automation not only improves operational efficiency but also enhances the overall quality of diagnostic testing.

### Growing Investment in Healthcare Infrastructure

The ongoing investment in healthcare infrastructure in the US is a significant driver for the virology specimen-collection market. As healthcare facilities expand and modernize, there is an increasing need for advanced specimen-collection technologies to support enhanced diagnostic capabilities. Government initiatives aimed at improving healthcare access and quality are likely to result in substantial funding for laboratory upgrades and new equipment. Recent reports suggest that healthcare infrastructure spending is projected to increase by approximately 12% over the next few years. This trend indicates that the virology specimen-collection market will benefit from improved facilities and resources, ultimately leading to better patient care and more efficient specimen-collection processes.

### Increased Focus on Infectious Disease Surveillance

The growing emphasis on infectious disease surveillance in the US is a critical driver for the virology specimen-collection market. Public health agencies are prioritizing the monitoring of viral outbreaks to ensure timely responses and effective containment strategies. This focus has led to increased funding for surveillance programs, which in turn drives demand for specimen-collection services. Data from health organizations indicate that funding for infectious disease surveillance has seen a notable increase, with allocations rising by approximately 15% in recent years. This trend suggests that the virology specimen-collection market will benefit from enhanced resources and support, enabling more comprehensive data collection and analysis to inform public health decisions.

## Future Outlook

The [Virology Specimen Collection Market](https://www.marketresearchfuture.com/reports/virology-specimen-collection-market-10798) is projected to grow at a 5.3% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for diagnostic testing.

**New opportunities:**

- Development of mobile specimen-collection units for remote areas. Integration of AI for enhanced specimen analysis and tracking. Expansion of partnerships with healthcare providers for streamlined collection services.

By 2035, the market is expected to achieve robust growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Swabs (Largest) vs. Viral Transport Media (Fastest-Growing)

In the US virology specimen-collection market, Swabs hold the largest market share due to their widespread use in various diagnostic procedures. This segment's dominance is rooted in their effectiveness and ease of use in collecting specimens from patients, making them a preferred choice among healthcare professionals. On the other hand, Viral Transport Media is gaining traction, showcasing a rapid increase in demand as laboratories seek efficient solutions for transporting viral samples without compromising their integrity over time.\n\nThe market trends indicate that as the necessity for reliable and accurate testing continues to rise, the demand for both Swabs and Viral Transport Media will follow suit. The growth drivers include the ongoing emphasis on public health initiatives and the increasing incidence of viral infections, further elevating the relevance of these specimen-collection types. As technology advances, innovative solutions within these segments are expected to attract both investments and heightened interest from stakeholders.

Swabs (Dominant) vs. Viral Transport Media (Emerging)

Swabs are recognized as the dominant player in the specimen-collection segment, primarily used for their versatility and efficiency in several diagnostic applications. Their wide usage ranges from rapid tests for infectious diseases to routine screening procedures, solidifying their significant market position. In contrast, Viral Transport Media serves as an emerging segment, crucial for preserving viral samples during transit. This type is essential as it ensures the viability of specimens until they reach laboratories for analysis. As awareness about proper specimen handling rises, both segments are likely to see continued interest, with Swabs maintaining their dominance while Viral Transport Media positions itself as a vital component of reliable virology testing.

### By Application: Diagnostics (Largest) vs. Research (Fastest-Growing)

In the US virology specimen-collection market, the application segment is primarily dominated by diagnostics, which holds the largest market share due to the increasing need for early detection and monitoring of viral infections. Diagnostics solutions are heavily utilized in clinical laboratories, hospitals, and point-of-care settings, thereby ensuring a robust foundation for this segment's sustainability and growth. In contrast, the research segment, while smaller, is rapidly gaining traction as more funding and interest in virology research expands, particularly in academic and pharmaceutical settings.

The growth trends in the US virology specimen-collection market indicate that the diagnostics application will continue to maintain its dominance, supported by advancements in technology and an increasing focus on preventive healthcare measures. Meanwhile, the research application segment is expected to outpace diagnostics in terms of growth rate, driven by innovations in virology studies, vaccine development, and the need for enhanced understanding of viral diseases. This convergence of increased research activities and advancements in specimen collection technologies will pave the way for new opportunities within this segment.

Diagnostics (Dominant) vs. Research (Emerging)

The diagnostics segment dominates the US virology specimen-collection market due to the essential role it plays in identifying viral infections swiftly and accurately. This segment comprises various kits and platforms that offer diverse testing capabilities. Diagnostics solutions are characterized by their reliability and efficiency, making them a preferred choice for healthcare providers. On the other hand, the research segment is emerging as a vital element of the market, focusing on virology advancements and innovative methodologies. Research caters to academic institutions and laboratories that are exploring new viral therapies and vaccines, and is characterized by a flexible and innovative approach to specimen collection, often integrating cutting-edge technology to enhance research outcomes. Both segments are vital, but their market dynamics vary significantly.

### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US virology specimen-collection market, Hospitals & Clinics hold the largest market share. This segment benefits from the significant patient footfall and the prevalence of various viral infections requiring efficient specimen collection. Diagnostic Centers, though smaller in market share, are experiencing rapid growth due to the increasing demand for specialized testing and the rise of outpatient services.

The growth dynamics for the End User segment are primarily driven by technological advancements and the expanding healthcare infrastructure. Hospitals & Clinics are leveraging innovations in specimen collection techniques to enhance efficiency, while Diagnostic Centers are rapidly emerging as essential entities for swift and accurate testing. The growing awareness of viral diseases among the population is further propelling the demand across all segments, particularly for rapid diagnostic services.

Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals & Clinics are characterized by their comprehensive healthcare services and advanced laboratory capabilities, making them a fundamental pillar in the US virology specimen-collection market. They dominate the market due to their ability to handle high patient volumes and their established protocols for specimen collection. In contrast, Diagnostic Centers are emerging as vital players, focusing on specialized virology testing services, which enables them to cater to niche markets. This segment is gaining traction due to its agility and ability to provide rapid results, thus responding to the increasing consumer demand for timely and accurate healthcare solutions. As the healthcare landscape evolves, both segments will play crucial roles in shaping the future of virology specimen collection.

## Competitive Benchmarking

The virology specimen-collection market is characterized by a dynamic competitive landscape, driven by the increasing demand for efficient diagnostic solutions and advancements in technology. Key players such as Thermo Fisher Scientific (US), Abbott Laboratories (US), and Roche Diagnostics (CH) are strategically positioned to leverage innovation and expand their market presence. Thermo Fisher Scientific (US) focuses on enhancing its product portfolio through continuous research and development, while Abbott Laboratories (US) emphasizes strategic partnerships to bolster its diagnostic capabilities. Roche Diagnostics (CH) is known for its commitment to integrating digital solutions into its operations, thereby enhancing the efficiency of specimen collection processes. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and operational efficiency.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation. The collective influence of these major players shapes the market structure, as they continuously adapt to changing consumer demands and regulatory requirements.
In October Abbott Laboratories (US) announced a partnership with a leading telehealth provider to enhance remote specimen collection capabilities. This strategic move is likely to expand Abbott's reach in the growing telehealth sector, allowing for more accessible diagnostic services. By integrating telehealth solutions, Abbott aims to streamline the specimen collection process, thereby improving patient experience and operational efficiency.
In September Thermo Fisher Scientific (US) launched a new line of automated specimen collection devices designed to improve accuracy and reduce contamination risks. This innovation is significant as it aligns with the increasing demand for high-quality diagnostic tools. The introduction of these devices may position Thermo Fisher as a leader in the automation of specimen collection, potentially enhancing its competitive edge in the market.
In August Roche Diagnostics (CH) expanded its digital health platform to include advanced analytics for specimen tracking and management. This expansion is indicative of Roche's commitment to digital transformation, which is becoming increasingly vital in the healthcare sector. By enhancing its digital capabilities, Roche is likely to improve operational efficiencies and provide better insights into specimen management, thereby strengthening its market position.
As of November current trends in the virology specimen-collection market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into operations. Strategic alliances are increasingly shaping the competitive landscape, as companies seek to combine resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and enhanced customer experiences. This shift suggests that companies that prioritize these areas may be better positioned to thrive in the future.

## Recent News & Developments

In recent months, the US Virology Specimen Collection Market has seen significant developments, particularly spurred by advancements in diagnostic capabilities due to increased demand for testing amid ongoing health concerns. Companies such as Hologic and Abbott Laboratories have reported growth in their product offerings, expanding their virology-related diagnostic tools. Additionally, in March 2023, Roche and Cepheid collaborated to enhance their collection methods for better efficiency and accuracy. The year 2022 marked a pivotal moment when Medline Industries introduced new logistics services to streamline specimen transportation, positively impacting market dynamics.

Furthermore, in July 2023, PerkinElmer announced an acquisition of SeraCare Life Sciences, aiming to strengthen its portfolio in molecular diagnostics. As the market continues to evolve, the focus on Research and Development activities remains crucial, with significant investments from Thermo Fisher Scientific and BioRad Laboratories being reported to improve specimen handling technologies. With the rise of personalized medicine and rapid testing scenarios, there is a robust upward trajectory in market growth, driven by innovation and strategic partnerships among key players in the industry.

## Report Scope

| MARKET SIZE 2024 | 1798.55(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1893.88(USD Million) |
| MARKET SIZE 2035 | 3174.92(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), BD (US), Qiagen (DE), PerkinElmer (US), Hologic (US), Bio-Rad Laboratories (US), Merck KGaA (DE) |
| Segments Covered | Type, Application, End User |
| Key Market Opportunities | Integration of advanced digital technologies enhances efficiency in the virology specimen-collection market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the virology specimen-collection market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US virology specimen-collection market?**
A: The market valuation was $1798.55 Million in 2024.

**Q: What is the projected market size for the US virology specimen-collection market by 2035?**
A: The projected valuation for 2035 is $3174.92 Million.

**Q: What is the expected CAGR for the US virology specimen-collection market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.3% during the forecast period.

**Q: Which segments are included in the US virology specimen-collection market?**
A: Key segments include Swabs, Viral Transport Media, Blood Collection Kits, and Others.

**Q: What was the market size for Swabs in 2024?**
A: The market size for Swabs ranged from $600.0 Million to $1100.0 Million in 2024.

**Q: How does the market for Viral Transport Media compare to Blood Collection Kits?**
A: Viral Transport Media had a market size of $500.0 Million to $900.0 Million, while Blood Collection Kits ranged from $400.0 Million to $800.0 Million.

**Q: What applications are driving the US virology specimen-collection market?**
A: The market is driven by Diagnostics and Research applications, each valued between $899.275 Million and $1587.46 Million.

**Q: Who are the key players in the US virology specimen-collection market?**
A: Key players include Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, and BD, among others.

**Q: What is the market size for hospitals and clinics in the US virology specimen-collection market?**
A: The market size for Hospitals & Clinics was between $899.275 Million and $1587.46 Million in 2024.

**Q: What is the expected growth trend for diagnostic centers in the US virology specimen-collection market?**
A: The market size for Diagnostic Centers is projected to grow from $719.64 Million to $1265.46 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-virology-specimen-collection-market-16390*